Galecto, based on research at Lund and Edinburgh universities, is merging with PharmAkea, with the joint entity retaining the Galecto name and leadership team.
Galecto Biotech, a Denmark-based cancer and fibrosis treatment developer based on research at Lund University and University of Edinburgh, disclosed on Tuesday that it will merge with US-based peer PharmAkea.
Financial terms of the transaction have not been disclosed. The joint entity will operate under the Galecto name and will be led by the latter’s existing senior management team, including chief executive Hans Schambye.
Galecto will be incorporated in the US, with an office located on the East…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
